SOPs for Drug Discovery

The purpose of this Standard Operating Procedure (SOP) is to describe the process for applying omics data in target validation during drug discovery. Omics technologies, including genomics, proteomics, metabolomics, and transcriptomics, provide high-throughput data that can identify potential drug targets and validate their relevance in disease mechanisms. This SOP ensures that omics data are systematically integrated into the target validation process to enhance the discovery of novel therapeutic targets and improve drug development outcomes.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process for assessing the drug-likeness parameters of compounds during the early stages of drug discovery. Drug-likeness refers to the chemical and pharmacological properties of a compound that are favorable for development as a drug candidate. This SOP ensures that drug-likeness is systematically evaluated using computational and experimental methods to select lead compounds with optimal drug-like characteristics.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the use of Artificial Intelligence (AI) and Machine Learning (ML) techniques in drug discovery. AI and ML are powerful computational tools that enable the identification of new drug candidates by predicting biological activity, optimizing chemical structures, and analyzing large-scale biological data. This SOP ensures that AI and ML technologies are applied systematically, efficiently, and ethically to enhance the drug discovery process, from target identification to lead optimization.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for the synthesis of lead compounds in drug discovery. The synthesis of lead compounds is a crucial step in the drug development process, enabling the generation of compounds that can be tested for biological activity and optimized for therapeutic use. This SOP ensures that lead compounds are synthesized efficiently, safely, and in compliance with regulatory guidelines, enabling their use in further drug discovery efforts.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for predicting the toxicity of lead compounds during the lead optimization phase of drug discovery. Toxicity prediction is a crucial step in identifying and mitigating potential adverse effects early in the drug development process. This SOP ensures that toxicity prediction is performed systematically using computational models, in silico tools, and experimental data to inform the optimization of lead candidates.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for conducting ADME (Absorption, Distribution, Metabolism, and Excretion) screening during the early stages of drug discovery. ADME screening is crucial for evaluating the pharmacokinetic properties of potential drug candidates to determine their suitability for further development. This SOP ensures that ADME screening is conducted systematically and effectively to assess the drug-likeness of lead compounds and identify potential candidates for optimization.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of pharmacophore modeling in drug discovery. Pharmacophore modeling is a computational technique used to identify the essential chemical features required for a molecule to interact with a specific biological target. The aim is to design or screen for compounds that contain the key pharmacophoric features for binding to a target, thereby facilitating the identification of new drug candidates. This SOP ensures that pharmacophore modeling is conducted systematically and efficiently, using validated tools and methods to identify and optimize lead compounds.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of selecting molecular scaffolds in drug discovery. Molecular scaffolds serve as the core structure of drug molecules and are critical in the design of novel compounds with desired biological activity. This SOP ensures that scaffold selection is carried out systematically, using both computational and experimental approaches to identify scaffolds with optimal properties for lead optimization and further drug development.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of lead optimization in drug discovery. Lead optimization is the phase in drug development where the chemical structure of lead compounds is modified to improve their potency, selectivity, pharmacokinetic properties, and overall drug-likeness. This SOP ensures that lead optimization is carried out systematically, with appropriate computational tools, experimental validation, and consideration of regulatory guidelines to identify the best candidates for clinical development.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process for identifying and prioritizing hits during the drug discovery process. Hit identification is a critical step where compounds that exhibit desired biological activity against a specific target are selected from large compound libraries or screening assays. Prioritization ensures that the most promising candidates are advanced for further development and optimization. This SOP ensures that hit identification and prioritization are conducted in a consistent, reproducible, and systematic manner to support efficient drug discovery efforts.
Click to read the full article.